Dallas, TX, United States of America

Jacob E Lackovic


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2024-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Jacob E. Lackovic: Innovator in Migraine Therapy

Introduction

Jacob E. Lackovic is a notable inventor based in Dallas, TX (US). He has made significant contributions to the field of migraine therapy, holding 2 patents that focus on innovative methods for preventing and treating migraines. His work is particularly relevant for individuals suffering from this debilitating condition.

Latest Patents

Lackovic's latest patents include a method for regulating eIF4E activity for migraine therapy. This patent outlines a method of preventing, treating, or inhibiting migraines in a subject by administering a therapeutic agent selected from cercosporamide, eFT508, or 4EGI-1. The disclosure also includes compositions that combine these agents in amounts sufficient to effectively manage migraines, along with a pharmaceutically acceptable carrier. This innovative approach aims to provide relief for those affected by migraines through targeted therapeutic strategies.

Career Highlights

Jacob E. Lackovic is affiliated with the University of Texas System, where he continues to advance research in migraine therapies. His work is characterized by a commitment to developing effective treatments that can significantly improve the quality of life for migraine sufferers.

Collaborations

Lackovic collaborates with Greg Dussor, a fellow researcher, to further explore the mechanisms and treatments related to migraine therapy. Their combined expertise enhances the potential for groundbreaking discoveries in this area.

Conclusion

Jacob E. Lackovic stands out as an innovative inventor dedicated to improving migraine treatment through his patented methods and compositions. His contributions to the field are paving the way for more effective therapies that can alleviate the suffering of many individuals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…